EXHIBIT 99.1

FOR IMMEDIATE NEWS RELEASE

Contact:

Michael Jorgensen
Executive Vice President
   and Chief Financial Officer

DOBI Medical International, Inc.
1200 MacArthur Blvd.
Mahwah, NJ 07430
201-760-6464 x 208
201-760-8860 Fax
www.dobimedical.com


                     LIONS GATE INVESTMENT LIMITED ANNOUNCES
                            CORPORATE NAME CHANGE AND
                      CHANGE IN TRADING SYMBOL TO "DBMI.OB"

MAHWAH, NJ, JANUARY 30, 2004 - Lions Gate Investment Limited today announced
that it has changed its corporate name to DOBI Medical International, Inc., and
its state of incorporation to Delaware by means of a merger with and into a new
wholly-owned Delaware corporation called DOBI Medical International, Inc., with
DOBI Medical International surviving as the publicly-traded company. The
reincorporation will not change the day-to-day operations of DOBI Medical
International.

DOBI Medical International's new over-the-counter trading symbol is "DBMI.OB,"
under which it will begin trading at the opening of business today. Its new
CUSIP number is 256058-10-8.

Shareholders of Lions Gate have the right to receive one share of common stock
of DOBI Medical International for each share of Lions Gate owned by the
shareholder as of today, the effective date of the reincorporation. Shareholders
are not required to submit their existing Lions Gate stock certificates to the
company's transfer agent for reissuance on new DOBI Medical International stock
certificates. The company's transfer agent will continue to process transfers of
shares represented by existing Lions Gate stock certificates.

The total number of shares of capital stock which DOBI Medical International has
authority to issue is 150,000,000 shares, of which 140,000,000 shares are
designated as Common Stock, and 10,000,000 shares are designated as Preferred
Stock. Each share of Common Stock has a par value of $.000l, and each share of
Preferred Stock has a par value of $.000l.


                              *          *        *

DOBI Medical International is an advanced development-stage medical technology
imaging company developing a new means for the improved diagnosis of cancer
through the detection of vascular changes ("angiogenesis") associated
specifically with malignant tumors. DOBI Medical Systems, Inc., its wholly-owned
operating subsidiary, continues to conduct its business since it was acquired by
Lions Gate in the reverse merger transaction completed on December 9, 2003.

DOBI Medical's first application of its technology is the ComfortScan(TM)
system, a non-invasive, non-ionizing medical imaging system designed to assist
physicians in the detection of breast cancer at the earliest stages of
development. The ComfortScan system is intended to achieve this by providing
new, physiology-based imagery of vascular changes not readily available today.

Phillip C. Thomas, DOBI Medical International's Co-Founder and Chief Executive
Officer, commented, "I am very pleased to have completed this restructuring, and
we look forward to executing our business plan with this firm infrastructure and
building value for our stockholders."

FORWARD LOOKING STATEMENTS

This release contains certain "forward looking statements" relating to the
business of DOBI Medical International, which can be identified by the use of
forward looking terminology such as "believes," "expects" or similar
expressions. Such forward looking statements involve known and unknown risks and
uncertainties, including uncertainties relating to product development,
regulatory actions or delays, the ability to obtain or maintain patent or other
proprietary intellectual property protection, market acceptance, physician
acceptance, third party reimbursement, future capital requirements, competition
in general and other factors that may cause actual results to be materially
different from those described herein as anticipated, believed, estimated or
expected. Certain of these risks and uncertainties are or will be described in
greater detail in our filings with the U.S. Securities and Exchange Commission
from time to time, particularly our Jumbo Form 8-K filed on December 19, 2003
and our definitive Form 14C filed on January 9, 2004. DOBI Medical International
assumes no obligation to update information contained in this document,
including guidance regarding future performance, which represents the companies'
expectations only as of the date of this release and should not be viewed as a
statement about the companies' expectations after such date. Although this
release may remain available on our website or elsewhere, its continued
availability does not indicate that we are reaffirming or confirming any of the
information contained therein.


                                *****************